Peritoneal carcinomatosis 2011; it's about time for chemosurgery

Journal of B.U.ON.

Volumn 16, Issue 3, 2011, Pages 400-408

  Spiliotis, John D ^a   Halkia, E A ^a   Efstathiou, E ^a  

^a METAXA CANCER HOSPITAL   (Greece)

Author keywords

Colon cancer; Gastric cancer; HIPEC; Ovarian cancer; Peritoneal carcinomatosis

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; PACLITAXEL; PEMETREXED;

CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER PALLIATIVE THERAPY; CANCER SURGERY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CHEMOSURGERY; COLORECTAL CANCER; CYTOREDUCTIVE SURGERY; DRUG EFFICACY; HIGH RISK PATIENT; HYPERTHERMIC INTRAOPERATIVE INTRAPERITONEAL THERAPY; HYPERTHERMIC THERAPY; LAPAROSCOPY; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; OVARY CANCER; PATHOPHYSIOLOGY; PATIENT SELECTION; PERITONEUM MESOTHELIOMA; PERITONEUM PSEUDOMYXOMA; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMACH CANCER; SURVIVAL TIME; SYSTEMIC THERAPY; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

CARCINOMA; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; OVARIAN NEOPLASMS; PATIENT SELECTION; PERITONEAL NEOPLASMS; STOMACH NEOPLASMS;

EID: 80053971763     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Spiliotis JD. Peritoneal carcinomatosis, cytoreductive surgery and HIPEC: A ray of hope for cure. Hepatogastroenterology 2010; 103: 1173-1177.
2. Spiliotis JD, Vaxevanidou A, Datsis A, Rogdakis A, Kekelos S. Peritoneal carcinomatosis; intra-operative and postoperative assessment of patients undergoing cytoreduction and HLPEC. Hepatogastroenterology 2010; 103: 1052-1059.
3. Esquivel J. Cytoreductive surgery for peritoneal malignancies-development of standards of care for the community. Surg Onc Clin N Am 2007; 16: 653-666. (Pubitemid 46990950)
4. Al-Shammea H, Li Y, Yonemura Y. Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. World J Gastr 2008; 14: 1159-1166. (Pubitemid 351356322)
5. Sugarbaker P. Management of peritoneal surface malignancy: A short history. Rec Results Cancer Res 2007; 169: 1-9.
6. Liotta LA. Tumor invasion and metastases-role of the extra cellular matrix. Cancer Res 1986; 46: 1-7. (Pubitemid 16189019)
7. Yonemura Y, Bandou E, Kawamura T, Endou Y, Sasaki T. Quantitative prognostic indicators of peritoneal dissemination of gastric cancer. Eur J Surg Oncol 2006; 32: 602-606. (Pubitemid 44063992)
8. Sugarbaker P. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. Cancer Treat Res 1996; 82: 79-110.
9. Nissan A, Stojadinovic A, Garofalo A, Esquivel J, Piso P. Evidence-based medicine in the treatment of peritoneal carcinomatosis. Past, present and future. J Surg Oncol 2009; 100: 335-344.
10. Carmignani CP, Sugarbaker TA, Bromley CM, Sugarbaker PH. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rec 2003; 22: 465-472. (Pubitemid 36791900)
11. Sugarbaker PH. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. In: Sugarbaker PH (Ed): Peritoneal carcinomatosis. Principles of management. Kluwer Publ, Boston, 1996, pp 79-100.
12. Sugarbaker P, Yonemura Y. Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure. Oncology 2000; 58: 96-107.
13. Yan TD, Black D, Savady R, Sugarbaker PH. Systemic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 2006; 24: 4011-4019. (Pubitemid 46630752)
14. Chu SR, Rubin SC. Second look laparotomy for epithelial ovarian cancer: a reappraisal. Curr Oncol Rep 2001; 3: 11-18.
15. Deraco M, Baratti D, Zaffaroni N, Cabras AD, Kusamure S. Advances in clinical research and management of diffuse peritoneal mesothelioma. Recent Res Cancer Treat 2007; 169: 137-155.
16. Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
17. Sugarbaker PH. Peritonectomy procedures. Cancer Treat Res 2007; 2134: 247-264.
18. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In: Sugarbaker P (Ed): Peritoneal carcinomatosis. Principles of management. Kluwer Publ, Boston, 1996, pp 359-374.
19. Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999; 6: 727-731. (Pubitemid 30013648)
20. Stewart JH, Shen P, Lerine EA. Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy. Current status and future directions. Ann Surg Oncol 2005; 12: 756-777.
21. Elias D, Bonney M, Puizillou JM et al. Heated intra-peritoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance. Ann Oncol 2004; 15: 1558-1565. (Pubitemid 39409748)
22. Sugarbaker P, Stuart OA Carmignanic P. Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin. Cancer Chemother Pharmacol 2006; 57: 703-708.
23. El Kareh AW, Secomb TW. A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance. Neoplasia 2004; 6: 117-127. (Pubitemid 38544599)
24. VanderWaal R, Thampy G, Wright WD, Roti Roti JL. Heat-induced modifications in the association of specific proteins with the nuclear matrix. Radiat Res 1996; 145: 746-753. (Pubitemid 26159523)
25. Pelz JD, Doerfer J, Hohenberger N, Meyer T. A new survival model for HIPEC in tumor bearing rats in the treatment of peritoneal carcinomatosis. BMC Cancer 2005; 5: 56-59.
26. Spiliotis J, Tentes A, Vaxevanidou A et al. Cytoreductive surgery and HIPEC in the management of peritoneal carcinomatosis. Preliminary results and costs from 2 centers in Greece. J BUON 2008; 13: 205-210. (Pubitemid 351836702)
27. Glockzin G, Schlitt H, Piso P. Peritoneal carcinomatosis, patient selection, perioperative complications and quality of life related to cytoreductive surgery and HPEC. World J Surg Oncol 2009; 7: 5-9.
28. Sugarbaker PH. Epithelial appendiceal neoplasms. Cancer J 2009; 15: 225-235.
29. Kerscher A, Esquivel J. Current status, future directions: management of colon cancer with peritoneal dissemination. Future Oncol 2008; 4: 671-679.
30. Di Giorgio A, Naticchioni E, Biacehi D et al. Cytoreductive surgery combined with HIPEC in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer 2008; 113: 315-325.
31. Halkia E, Kyriazanos J, Efstathiou E, Spiliotis J. Laparoscopic cytoreductive surgery and HIPEC in the management of peritoneal carcinomatosis. Hepatogastroenterology 2011 (in press).
32. Facchiano E, Scaringi S, Kianmanesh R et al. Laparoscopic HIPEC for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced pancreatic cancer. Eur J Surg Oncol 2008; 34: 154-158.
33. Bozzetti F, Yu W, Baratti D, Kusamura S, Deraco M. Locoregional treatment of peritoneal carcinomatosis from gastric cancer. J Surg Oncol 2008; 98: 273-276.
34. Esquivel J, Sticca R, Sugarbaker P et al. Cytoreductive surgery and MPEC in the management of peritoneal surface malignancy of colonic origin: A consensus statement. Ann Surg Oncol 2007; 14: 128-133. (Pubitemid 44954279)
35. Helm CW, Bristow R, Kusamura S, Baratti D, Deraco M. HIPEC with and without cytoreductive surgery for epithelial ovarian cancer. J Surg Oncol 2008; 98: 283-290.
36. Sakuramoto S, Sasoko M, Yamaguchi et al. Adjuvant chemotherapy for GC with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-1820. (Pubitemid 350044801)
37. Juhl H, Stritzel M, Wroblewski A et al. Immunocytological detection of micrometastatic cells: comparative evaluation of findings in the peritoneal cavity and the bone marrow of gastric, colorectal and pancreatic cancer patients. Int J Cancer 1994; 57: 330-335. (Pubitemid 24168605)
38. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomized trials. Eur J Cancer 1999; 35: 1059-1064. (Pubitemid 29339187)
39. Cunningham D, Allum WH, Stenning SP et al. MAGIC trial participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
40. Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730.
41. Cervantes A, Rosello S, Roda D, Rodriguez-Brawn E. The treatment of advanced gastric cancer: current strategies and future perspectives. Ann Oncol 2008; 19(5S): 103-107.
42. Yan TD, Black D, Sugarbaker P et al. A systemic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol 2007; 14: 2702-2713. (Pubitemid 47460649)
43. Yonemura Y, Elnemr A, Endou Y et al. Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J Gastrointest Oncol 2010; 2: 85-97.
44. Yang XJ, Huang CQ, Su OT et al. Cytoreductive surgery and HIPEC improves survival of patients with peritoneal carcinomatosis from gastric cancer. Results of a phase III randomized clinical trial. Ann Surg Oncol 2011; 18: 1575-1581.
45. Spiliotis J, Halkia E. Slow progress in predicting and preventing fatal gastric cancer peritoneal recurrence. Ann Surg Oncol 2011 (accepted for publication).
46. Jayne DG, Fook S, Loi C et al. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002; 89: 1545-1550.
47. Folprecht G, Kohne CH, Lutz MP. Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. Cancer Treat Res 2007; 134: 425-440.
48. Mohamed F, Cecil T, Moran B, Sugarbaker P. A new standard of care for the management of peritoneal surface malignancy Curr Oncol 2011; 18: e84-e97.
49. Sanoff HK, Sargent DJ, Campbell ME et al. Five year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 2008; 26: 5721-5727.
50. Elias D, Lefevre J, Chevalier J et al. Complete cytoreductive surgery plus chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009; 27: 681-685.
51. Venvaal VJ, van Ruth S, deBree E et al. Randomized trial of cytoreduction and HIPEC versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2003; 21: 3737-3743.
52. Glehen O, Kwiatkowski F, Sugarbaker PH et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004; 22: 3284-3292. (Pubitemid 41103684)
53. Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. A 8-year follow up of randomized trial: cytoreduction and HIPEC versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008; 15: 2426-2432.
54. Verwaal VJ. Long-term results of cytoreduction and HIPEC followed by systemic chemotherapy. Cancer 2009; 15: 212-215.
55. Esquivel J, Stojadinovic A, Levine EA. The American Society of peritoneal surface malignancies. Ann Surg Oncol 2010; 11: 13-14.
56. Elias D, Goere D, DiPetronio D et al. Results of systematic second look in patients at high risk of developing colorectal peritoneal carcinomatosis. Ann Surg 2008; 247: 445-450.
57. Tentes A, Spiliotis J, Korakianitis O, Vaxevanidou A, Kyziridis D. Adjuvant perioperative intraperitoneal chemotherapy in locally advanced colorectal cancer: Preliminary results. ISRN Surgery 2011; ID 529876, 6 doi: 10.5401.
58. Ripley R, Davis J, Kemp C et al. Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs standard of care in patients at high risk of developing colorectal peritoneal metastases. Trials 2010; 11: 1-8.
59. Bijelic L, Jonson A, Sugarbaker P. Systemic review of CRS and HIPEC for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer. Ann Oncol 2007; 18: 1943-1950.
60. Jemal A, Segel R, Xu J, Word E. Cancer Statistics 2010. CA Cancer J Clin 2010; 60: 277-300.
61. Vergote I, Trope CG, Amant F et al. Neoadjuvant chemotherapy or primary surgery in stage TfIc or TV ovarian cancer. N Engl J Med 2010; 363: 943-953.
62. Spiliotis J, Vaxevanidou A, Sergouniotis F, Lambropoulou E, Datsis A, Christopoulou A. The role of CRS and HIPEC in the management of recurrent advanced ovarian cancer: A prospective study. J BUON 2011; 16: 74-79.
63. Bristow R, Tomecruz R, Armstrong D, Trimble E, Montz FJ. Survival effect of maximal cytoreduction for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 2002; 20: 1248-1259. (Pubitemid 34177431)
64. Armstrong DK, Bundy B, Wenzel L et al. Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354: 34-43. (Pubitemid 43048949)
65. Albers DS, Lin PY, Hannigen EV et al. Intraperitoneal cisplatinum plus iv cyclophosphamide versus intravenous cisplatinum plus iv cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335: 1950-1955.
66. Markman M, Bundy BN, Greer BE et al. Phase III trial of standard-dose iv cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by iv paclitaxel and IP cisplatin in small volume stage III ovarian carcinoma. J Clin Oncol 2001; 19: 1001-1007.
67. Piso P, Dahike MH, Loss M, Schlitt HJ. CRS and HIPEC in peritoneal carcinomatosis from ovarian cancer. World J Surg Oncol 2004; 2: 21-25.
68. Rufian S, Munoz-Casores FC, Briceno J et al. Radical surgery - peritonectomy and HIPEC for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol 2006; 94: 316-324. (Pubitemid 44330855)
69. Reichmon TW, Cracchiolo B, Sama J et al. CRS and HIPEC for advanced ovarian carcinoma. J Surg Oncol 2005; 90: 51-56.
70. Ceelen NP, Van Nieuwenhove Y, Van Belle S, Denys H, Pattyn P. Cytoreduction and HIPEC in women with heavily pretreated recurrent ovarian cancer. Ann Surg Oncol 2009; 29 doi 10.1245.
71. Esquivel J, Averbach A. Combined laparoscopic cytoreductive surgery and HIPEC in a patient with peritoneal mesothelioma. J Laparosc Adv Surg Tech 2009; 19: 505-507.
72. Esquivel J, Averbach A, Chua TC. Laparoscopic cytoreductive surgery and HIPEC in patients with limited PSM: Feasibility, morbidity and outcome in an early experience. Ann Surg 2011; 253: 764-768.
73. Lygidakis NJ, Patil A, Giannoulis K et al. Laparoscopic HIPEC as adjuvant modality following radical surgery for advanced rectal cancer. A new look to an old problem. Hepatogastroenterology 2010; 97: 73-75.
74. Spiliotis J, Halkia E, Roukos D. Ovarian cancer screening and peritoneal carcinomatosis: standards "omics" and miRNAs for personalized management. Expert Rev Molec Diagn 2011 (in press).
75. Baratti D, Kusamura S, Laterza B, Balestra MR, Deraco M. Early and long-term postoperative management following cytoreductive surgery and HIPEC. World J Gastr Oncol 2010; 15: 36-43.
76. Yan TO, Moran BJ, Cecil T, Murphy EM. Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma. Eur J Surg Oncol 2009; 35: 980-985.
77. Baratti D, Kusamura S, Cobras AD et al. Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 2010; 17: 45-53.